Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 25217 results found since Jan 2013.
MicroRNA-143 as a potential tumor suppressor in cancer: An insight into molecular targets and signaling pathways
Pathol Res Pract. 2023 Sep 6;250:154792. doi: 10.1016/j.prp.2023.154792. Online ahead of print.ABSTRACTMicroRNAs (MiRNAs), which are highly conserved and small noncoding RNAs, negatively regulate gene expression and influence signaling pathways involved in essential biological activities, including cell proliferation, differentiation, apoptosis, and cell invasion. MiRNAs have received much attention in the past decade due to their significant roles in cancer development. In particular, microRNA-143 (miR-143) is recognized as a tumor suppressor and is downregulated in most cancers. However, it seems that miR-143 is upregula...
Source: Pathology, Research and Practice - September 9, 2023 Category: Pathology Authors: Vahid Asghariazar Mahtab Kadkhodayi Mehdi Sarailoo Amir Ghaffari Jolfayi Behzad Baradaran Source Type: research
Clinical Significance of Radical Prostatectomy in Clinical Lymph Node Metastasis in Prostate Cancer
CONCLUSION: Radical prostatectomy can confirm lymph node metastasis. Although pathologic diagnosis has no effect on time to BCR and CPRC, because it affects BCR rate, CRPC rate, and CSS, an accurate pathological diagnosis obtained through surgery is beneficial in the treatment of clinical lymph node metastasis prostate cancer.PMID:37689608 | DOI:10.1245/s10434-023-14137-4
Source: Ann Oncol - September 9, 2023 Category: Cancer & Oncology Authors: Dongwon Kim Bumjin Lim Jungyo Suh Dalsan You In Gab Jeong Jun Hyuk Hong Hanjong Ahn Source Type: research
External Validation of the IMPROD-MRI Volumetric Model to Predict the Utility of Systematic Biopsies at the Time of Targeted Biopsy
Conclusions: This study supports the potential value of a model relying on MRI volumetric measurements for selecting individuals with clinical suspicion of prostate cancer who would benefit from undergoing a standard biopsy in addition to a targeted biopsy.PMID:37685815 | PMC:PMC10488903 | DOI:10.3390/jcm12175748
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Antonella Ninivaggi Francesco Guzzi Alessio Degennaro Anna Ricapito Carlo Bettocchi Gian Maria Busetto Francesca Sanguedolce Paola Milillo Oscar Selvaggio Luigi Cormio Giuseppe Carrieri Ugo Giovanni Falagario Source Type: research
Prostate Biopsy in the Case of PIRADS 5-Is Systematic Biopsy Mandatory?
J Clin Med. 2023 Aug 28;12(17):5612. doi: 10.3390/jcm12175612.ABSTRACTCombining systematic biopsy (SB) with targeted biopsy (TB) in the case of a positive result from multiparametric magnetic resonance imaging (mpMRI) is a matter of debate. The Prostate Imaging Reporting and Data System (PIRADS) score of 5 indicates the highest probability of clinically significant prostate cancer (csPC) detection in TB. Potentially, omitting SB in the case of PIRADS 5 may have a marginal impact on the csPC detection rate. The aim of this study was to determine whether SB can be avoided in the case of PIRADS 5 and to identify potential fac...
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Wojciech Malewski Tomasz Milecki Stanis ław Szempliński Omar Tayara Łukasz Kuncman Piotr Kryst Łukasz Nyk Source Type: research
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
J Clin Med. 2023 Aug 28;12(17):5604. doi: 10.3390/jcm12175604.ABSTRACTRadium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra223-induced PSA flares on patient outcome. Using a retrospective cohort study of Ra223 treatment in four Ontario/Canada cancer centres, we identified 134 patients grouped into sub-cohorts according to distinct PSA response patterns: (i) initial PSA flare follow...
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Amanjot Sidhu Nabeeha Khan Cameron Phillips Juan Briones Anil Kapoor Pawel Zalewski Neil E Fleshner Edward Chow Urban Emmenegger Source Type: research
The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases
CONCLUSIONS: Brain metastases are an unfavorable prognostic factor in prostate cancer. The therapeutic options developed in recent years allow the improvement of survival.PMID:37685646 | PMC:PMC10488423 | DOI:10.3390/jcm12175579
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Roxana-Andreea Rahnea-Nita Laura-Florentina Rebegea Alexandru Nechifor Cristian Mare ș Radu-Valeriu Toma Alexandru-Rares Stoian Anda-Natalia Ciuhu Liliana-Florina Andronache Georgiana Bianca Constantin Gabriela Rahnea-Nita Source Type: research
The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma
In this study, we aimed to evaluate the biomarker potential and effect of PNI in determining the prognosis of metastatic castration-sensitive prostate cancer (mCSPC). This retrospective observational study included the complete data of 108 patients with mCPSC who were treated for at least three months between 1 January 2010, and 1 June 2021. The relationships between cancer-specific survival (CSS), overall survival (OS), progression-free survival (PFS), and PNI were evaluated. The Kaplan-Meier method for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models, were used for the statistical analyses. ...
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Halil Ibrahim Ellez Merve Keskinkilic H üseyin Salih Semiz Mehmet Emin Arayici Erdem K ısa Ilhan Oztop Source Type: research
Collection of cancer-specific data in population-based surveys in low- and middle-income countries: A review of the demographic and health surveys
PLOS Glob Public Health. 2023 Sep 8;3(9):e0002332. doi: 10.1371/journal.pgph.0002332. eCollection 2023.ABSTRACTPopulation-based surveys, such as those conducted by the Demographic and Health Surveys (DHS) Programme, can collect and disseminate the data needed to inform cancer control efforts in a standardised and comparable manner. This review examines the DHS questionnaires, with the aim of describing and analysing how cancer-specific questions have been asked from the inception of the surveys to date. A systematic search of the DHS database was conducted to identify cancer-specific questions asked in surveys. Descriptive...
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Chukwudi A Nnaji Jennifer Moodley Source Type: research
Reduction of PTV margins for elective pelvic lymph nodes in online adaptive radiotherapy of prostate cancer patients
CONCLUSION: It is safe to reduce the PTV margin from 5 to 4 mm for the elective pelvic lymph nodes for prostate patients treated with oART. Further margin reductions can be motivated for patients presenting little intrafraction motion.PMID:37682727 | DOI:10.1080/0284186X.2023.2252584
Source: Acta Oncologica - September 8, 2023 Category: Cancer & Oncology Authors: John Alfred Brenns æter Tordis Johnsen Dahle Jannicke N økling Moi Ingvild F ørsvoll Svanberg Gry Sandvik Haaland Sara Pilskog Source Type: research
Sustainable Nanoparticles from Stephania glabra and Analysis of Their Anticancer Potential on 2D and 3D Models of Prostate Cancer
Appl Biochem Biotechnol. 2023 Sep 8. doi: 10.1007/s12010-023-04700-w. Online ahead of print.ABSTRACTIn pursuit of a novel effective treatment for prostate cancer, methanolic extract of Stephania glabra tubers (Sg-ME) was utilized to fabricate silver (Sg-AgNP), copper oxide (Sg-CuONP), and silver-copper bimetallic nanoparticles (Sg-BNP). The characterization of the nanoparticles confirmed spherical shape with average diameters of 30.72, 32.19, and 25.59 nm of Sg-AgNP, Sg-CuONP, and Sg-BNP, respectively. Interestingly, these nanoparticles exhibited significant cytotoxicity toward the prostate cancer (PC3) cell line while bei...
Source: Applied Biochemistry and Biotechnology - September 8, 2023 Category: Biochemistry Authors: Prachi Vaid Adesh K Saini Raju Kumar Gupta Eshu Singhal Sinha Deepak Sharma Walaa F Alsanie Vijay Kumar Thakur Reena V Saini Source Type: research
Intravenous Pyogenic Granuloma in the Inguinal Canal Mimicking Lymph Node Metastasis on PSMA PET/CT
We present a 68-year-old man with newly diagnosed high-risk prostate cancer who was referred for PSMA PET/CT after the initial CT showed a contrast-enhanced structure resembling a lymph node in the left inguinal canal. No other findings suggesting metastatic disease were seen on CT or bone scintigraphy. PSMA PET/CT showed moderate PSMA uptake in the inguinal tissue, substantiating an unexpected location of lymph node metastasis. The uncommon location warranted an excision biopsy, and an IV pyogenic granuloma was diagnosed on histological examination, emphasizing the importance of biopsy of unexpected findings.PMID:37682620...
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Sarah Md Skyum Andrea K Anthonsen Giedrius Salkus Dmitry Kvon Helle D Zacho Source Type: research
Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies
CONCLUSIONS: 18F-DCFPyL PET/MRI excluded nearly 30% of patients with low-/intermediate-risk PCa from FT, with a potential role in decreasing selection failure. Compared with mpMRI, PET/MRI had a higher sensitivity for detecting csPCa in men who were candidates for FT.ClinicalTrials.gov identifier NCT03149861.PMID:37682613 | DOI:10.1097/RLU.0000000000004819
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Adriano Basso Dias Sangeet Ghai Claudia Ortega Seyed Ali Mirshahvalad Nathan Perlis Alejandro Berlin Lisa Avery Patrick Veit-Haibach Theodorus van der Kwast Ur Metser Source Type: research
Noninvasive Verification of a Very Small Intraocular Prostate Carcinoma Metastasis by 68Ga-PSMA-11 PET/CT
Clin Nucl Med. 2023 Oct 1;48(10):915-916. doi: 10.1097/RLU.0000000000004790. Epub 2023 Aug 30.ABSTRACTA male patient underwent 68Ga-PSMA-11 PET/CT for the evaluation of a suspected intraocular metastasis in the right eye. Although the choroidal thickening was very small (4 × 2 mm), and ophthalmoscopy as well as MRI were inconclusive, PET/CT imaging showed distinct PSMA expression in the suspected lesion, confirming prostate cancer metastasis. The ability of dedicated PSMA ligand PET/CT imaging to detect small metastases, even with 68Ga-labeled ligands, has been demonstrated. Therefore, the use of further invasive diagnost...
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Ferdinand Ndum Philipp Seifert Martin Freesmeyer Falk G ühne Source Type: research
68Ga-PSMA-11 PET/CT in a Case of Isolated Parietal Peritoneal Metastasis From Prostate Adenocarcinoma
We present 68Ga-PSMA-11 PET/CT findings in a case of isolated parietal peritoneal metastasis from prostate adenocarcinoma 35 months after radical prostatectomy. The peritoneal metastases showed multifocal intense PSMA uptake, but subtle structural abnormalities on 68Ga-PSMA-11 PET/CT. The patient was subsequently treated with androgen deprivation therapy. The peritoneal metastases progressed 25 months after the initiation of androgen deprivation therapy and were removed surgically. Histologic and immunohistochemical evaluation revealed metastatic prostate adenocarcinoma with treatment-related neuroendocrine differentiation...
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Qian Zhao Aisheng Dong Changjing Zuo Source Type: research
